In patients with certain hematologic malignancies, the use of autologous T cells genetically
modified to express chimeric antigen receptors (CARs) has led to unprecedented clinical …

Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall
survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase …

Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have
reported results from either private institutional data or publicly available datasets. However, …

Purpose: The clinical utility of plasma cell-free DNA (cfDNA) has not been assessed prospectively
in patients with glioblastoma (GBM). We aimed to determine the prognostic impact of …

Multi-omic data, ie, clinical measures, radiomic, and genetic data, capture multi-faceted
tumor characteristics, contributing to a comprehensive patient risk assessment. Here, we …

Background Imaging of glioblastoma patients after maximal safe resection and chemoradiation
commonly demonstrates new enhancements that raise concerns about tumor progression…

Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor
receptor variant III (CAR T-EGFRvIII) have been developed and administered experimentally to …

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries
a dismal prognosis. The EGFR gene is among the most commonly deranged genes in GBM …

Background. Mibefradil (MIB), previously approved for treatment of hypertension, is a selective
T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs). To …

Background Glioblastoma (GBM) is associated with a high incidence of venous thromboembolism
(VTE), but there are little data to guide anticoagulation in patients with GBM, in whom …